Inventiva(US:IVA)2026-03-10 15:02Summary of Inventiva Conference Call Company Overview - Company: Inventiva (NasdaqGM:IVA) - Location: Dijon, France - Focus: Biotech company specializing in PPAR agonists, particularly lanifibranor for MASH (Metabolic Associated Steatotic Hepatitis) [6][7] Key Points Product Development - Lead Program: Lanifibranor, a pan PPAR agonist, currently in Phase 3 studies for MASH [5][6] - Enrollment: Completed in April 2024, with data readout expected in the second half of 2026 [7] - Market Potential: MASH market has gained attention, with Madrigal achieving over $1 billion in sales, indicating strong pharmaceutical interest [7] Clinical Data - Phase 2b Results: Showed a 26% placebo-adjusted NASH resolution rate and an 18% fibrosis improvement at a six-month time point [17] - Phase 3 Study (NATiV3): Enrolling approximately 1,000 patients, focusing on F2 and F3 fibrosis stages, with a higher percentage of diabetic patients compared to previous studies [20][21] Mechanism of Action - Lanifibranor's Mechanism: A novel scaffold that engages all PPAR isoforms with a favorable safety profile, aiming to minimize the adverse effects seen in previous PPAR therapies [14][15][56] Market Strategy - Target Population: Approximately 375,000 patients with F2 and F3 MASH under treatment care, with a focus on diabetic patients [37] - Competitive Advantage: Lanifibranor is expected to outperform competitors like Rezdiffra, which has a lower effect size [38] Safety and Tolerability - Safety Profile: Predicted to have a muted PPAR-gamma effect, leading to less weight gain and fluid retention compared to traditional PPAR agonists [55][57] - Dropout Rates: Maintained below 30%, indicating good patient retention and tolerability [61] Future Studies - Exploratory Cohort: Includes 410 patients with varying fibrosis stages (F1-F4) to gather safety data and inform future studies [73][75] - F4 Patient Population: Plans to conduct an outcome study focused on patients with portal hypertension, aiming for accelerated approval [80][81] Commercialization Plans - Market Entry: Plans to self-commercialize lanifibranor, leveraging the successful strategies of mid-size biotech companies like Madrigal [99] - Intellectual Property: Exclusivity for lanifibranor extends to 2041 based on polymorph patents, with composition of matter expiring in December 2026 [101] Additional Insights - Regulatory Alignment: Continuous dialogue with the FDA regarding the design of outcome studies, ensuring compliance with regulatory expectations [86] - Impact of Competitors: Positive outcomes from competitors' studies could validate the efficacy of lanifibranor and enhance its market position [94] This summary encapsulates the critical aspects of Inventiva's conference call, highlighting the company's strategic direction, product development, and market positioning in the biotech industry.